Blueprint Medicines Corp.

8 trials 2 recruiting Commercial sponsor

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

2 Recruiting

5 Completed trials

15 Countries active

10 Unique IMPs

100% Results reported

Phase II/III

Phase II

Phase I/II

Phase IV

Phase I (FiH)

Phase II/III: 1 Phase II: 2 Phase I/II: 2 Phase IV: 1 Phase I (FiH): 2

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Systemic mastocytosis 3 Indolent systemic mastocytosis 2

Top IMPs

AVAPRITINIB 3 BLU-222 1 BLU-263 PHOSPHATE 1 BLU-451 1 BLU-808 1 CARBOPLATIN 1 ELENESTINIB PHOSPHATE 1 FULVESTRANT 1 RIBOCICLIB 1

All trials

8 total

Phase 1/2 Study of BLU-451 in certain advanced cancers Pending

2022-502527-21-00 Phase I (FiH) 1 country BLU-451
A rollover study of avapritinib (also called BLU-285) in adults Who Participated in a Previous Avapritinib Study Recruiting

2024-514969-18-00 Phase IV 4 countries AVAPRITINIB
HARBOR: Study of BLU-263 for Indolent Systemic Mastocytosis Recruiting

2024-516728-32-00 Phase II/III 15 countries ELENESTINIB PHOSPHATE
Study of BLU-808 in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria Ended

2024-520031-33-00 Phase II 4 countries BLU-808
A Study of Avapritinib in Patients with Indolent and Systemic Mastocytosis Ended

2024-512585-34-00 Phase II 9 countries AVAPRITINIB
(VELA) Study of BLU-222 in Advanced Solid Tumors Ended

2022-502528-29-00 Phase I (FiH) 4 countries BLU-222; CARBOPLATIN; FULVESTRANT; RIBOCICLIB
Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE) Ended

2023-510144-20-00 Phase I/II 6 countries BLU-263 PHOSPHATE
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling Ended

2023-508617-16-00 Phase I/II 4 countries AVAPRITINIB

Showing 1–8 of 8 trials

← All sponsors A–Z